协调瘤抗原吸收和树突细胞激活由化学抗原受体
Yahya Mohammadzadeh1,2,3, Vojislav Gligorovski4,5, Olga Egorova1,3
1Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), 1015 Lausanne, Switzerland.
Science translational medicine
|December 17, 2025
概括
研究人员开发了一种用于树突细胞 (DC) 的教学化学抗原受体 (iCAR) 平台. 这种新的方法通过启用抗原吸收和T细胞初始化来增强DC介导的抗瘤免疫力,提供了一个有前途的癌症免疫疗法策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 有效的抗瘤免疫依赖于树突细胞 (DCs) 进行抗原处理和T细胞激活.
- 目前基于直流的癌症免疫疗法显示出混合的临床反应,需要改进策略.
- 化学抗原受体 (CARs) 为增强DC功能提供了一个潜在的途径.
研究的目的:
- 开发和优化CARs用于基于DC的癌症免疫疗法.
- 创建一个可诱导的CAR (iCAR) 平台,用于增强DC识别和激活.
- 在临床前癌症模型中评估iCAR-engineered DCs (iCAR-DCs) 的疗效.
主要方法:
- 对一组CAR的选,以确定DC的关键功能组件.
- 构建一个可诱导的CAR (iCAR) 平台,使抗原识别和细胞因子生产成为可能.
- 在黑色素瘤模型中iCAR-DCs的体外和体外评估,评估T细胞反应和瘤生长.
主要成果:
- 该iCAR平台使DCs能够识别癌细胞和细胞外囊 (EVs) 上的瘤相关抗原 (例如GD2,HER2).
- 通过交叉穿戴和交叉呈现,iCAR-DCs促进T细胞原始化,并通过交叉呈现和交叉呈现来实现IL-12表达.
- 系统性给予iCAR-DCs增强了抗原特异性T细胞,扩大了T细胞克隆类型,并延迟了免疫治疗耐药黑色素瘤模型中的瘤生长.
结论:
- 该iCAR平台代表了一种新的方法,用于设计具有增强抗瘤功能的DC.
- iCAR-DCs可以将抗原吸收与可编程免疫刺激激活相结合,以有效的癌症免疫疗法.
- 这种抗原不可知论平台有可能在癌症治疗中得到广泛应用.
更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
54.0K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.2K
相关概念视频
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:22T Cell Activation and Clonal Selection
14.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.6K